News Releases


2018 | 2017 | 2016 | Archive
Keyword Search
 
DateTitle 
11/06/18ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results
-Third Quarter Net Sales Grew to $58.3 Million -Recently Announced Positive Top-line Results from the Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment for Major Depressive Disorder -FDA Issued Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis -Launched New Dosing Formulation and Strength of NUPLAZID ... 
Printer Friendly Version
10/31/18ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)
- Pimavanserin met primary endpoint with statistically significant overall improvement in HAMD-17 total score compared to placebo (p=0.039) - Pimavanserin met key secondary endpoint with statistically significant overall improvement in Sheehan Disability Scale compared to placebo (p=0.004) - Positive results also observed on seven additional secondary endpoints including responder rate, improvement in sexual function, and reduction... 
Printer Friendly Version
10/29/18ACADIA Pharmaceuticals Announces Executive Leadership Change
SAN DIEGO--(BUSINESS WIRE)--Oct. 29, 2018-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that Todd S. Young, Executive Vice President and Chief Financial Officer, will be leaving the organization effective October 31, 2018 to join another healthcare company. Elena Ridloff, CFA, Senior Vice President, Investor Relations will serve as the Company’s Interim Chief Financial Officer. “On behalf of the entire management team, I want to th... 
Printer Friendly Version
10/23/18ACADIA Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 6, 2018
ACADIA to Host Conference Call and Webcast on Tuesday, November 6, 2018, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Oct. 23, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the third quarter ended Sep... 
Printer Friendly Version
09/26/18ACADIA Pharmaceuticals Announces Executive Appointments to Lead Medical Affairs and Science
-Robert Kaper, M.D., named Senior Vice President, Global Head of Medical Affairs -Eliseo Salinas, M.D., M.Sc., named Senior Vice President, Chief Scientific Officer and Head of External Innovation SAN DIEGO--(BUSINESS WIRE)--Sep. 26, 2018-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous sys... 
Printer Friendly Version
09/25/18ACADIA Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference on October 2, 2018
SAN DIEGO--(BUSINESS WIRE)--Sep. 25, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 2018 Cantor Global Healthcare Conference on Tuesday, October 2, 2018, at 9:45 a.m. Eastern Time in New York City. A live webcast of ACADIA’s... 
Printer Friendly Version
09/20/18FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID® (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis
- FDA analysis finds no new or unexpected safety risks associated with NUPLAZID - Patients taking NUPLAZID for Parkinson’s disease psychosis should continue to use it as prescribed by their health care provider - FDA also reminds health care providers that no other antipsychotic medication is approved for the treatment of Parkinson’s disease psychosis SAN DIEGO--(BUSINESS WIRE)--Sep. 20, 2018-- ACADIA Pharmaceuticals Inc. (NASDAQ: AC... 
Printer Friendly Version
09/10/18Analyses of Pimavanserin Studies Evaluating Treatment in Alzheimer’s Disease Psychosis and Parkinson’s Disease Psychosis Published in The Journal of Prevention of Alzheimer’s Disease Suggest Potential for Treating Dementia-Related Psychosis
SAN DIEGO--(BUSINESS WIRE)--Sep. 10, 2018-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) announced today publication of additional data from a Phase 2 single center, double-blind, placebo-controlled study to examine the safety and efficacy of pimavanserin for the treatment of psychosis in Alzheimer’s Disease Psychosis in The Journal of Prevention of Alzheimer’s Disease (JPAD). These results further demonstrate that pimavanserin may have the potentia... 
Printer Friendly Version
09/04/18ACADIA Pharmaceuticals to Present at the Morgan Stanley 16th Annual Global Healthcare Conference on September 13, 2018
SAN DIEGO--(BUSINESS WIRE)--Sep. 4, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018, at 10:35 a.m. Eastern Time in New York City. A live ... 
Printer Friendly Version
08/08/18ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results
–Second Quarter Net Sales Grew to $57.1 Million, Representing a 17% Sequential Increase Over 1Q18 and 87% Increase Over 2Q17 –Announced FDA Approval of New Dosing Formulation and Strength of NUPLAZID® (Pimavanserin) –Expanded ACADIA’s Pipeline in Central Nervous System Disorders with Exclusive License Agreement for the North American Development and Commercialization of Trofinetide SAN DIEGO--(BUSINESS WIRE)--Aug. 8, 2018-- ... 
Printer Friendly Version
08/06/18ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License Agreement for the North American Development and Commercialization of Trofinetide in Rett Syndrome
-ACADIA plans to initiate a Phase 3 study of trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental congenital CNS disorder, in the second half of 2019 -Neuren retains all rights to trofinetide outside of North America -Neuren to receive US $10 million upfront plus potential milestones of up to US $455 million and royalties SAN DIEGO & MELBOURNE, Australia--(BUSINESS WIRE)--Aug. 6, 2018-- ACADIA Pharmaceu... 
Printer Friendly Version
07/30/18ACADIA Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 8, 2018
ACADIA to Host Conference Call and Webcast on Wednesday, August 8, 2018, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Jul. 30, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the second quarter ... 
Printer Friendly Version
07/19/18ACADIA Pharmaceuticals Announces Appointment of Austin D. Kim as Executive Vice President, General Counsel and Secretary
SAN DIEGO--(BUSINESS WIRE)--Jul. 19, 2018-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Austin D. Kim has joined ACADIA as Executive Vice President, General Counsel and Secretary. He will report to Steve Davis, ACADIA’s President and Chief Executive Officer and ... 
Printer Friendly Version
06/29/18ACADIA Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for NUPLAZID® (Pimavanserin)
– New Dosing Formulation and Strength Address Needs in Treating Patients with Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis SAN DIEGO--(BUSINESS WIRE)--Jun. 29, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced FDA approval of a new capsule dose formulation and a new tablet strength of NUPLAZID (pimavanserin) to help in the treatment of patients living with hallucinations and delusions associated wi... 
Printer Friendly Version
06/13/18ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 20, 2018
SAN DIEGO--(BUSINESS WIRE)--Jun. 13, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the JMP Securities Life Sciences Conference on Wednesday, June 20, 2018, at 11:30 a.m. Eastern Time in New York City. A live webcast of ACADIA’s... 
Printer Friendly Version
06/06/18ACADIA Pharmaceuticals to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on June 13, 2018
SAN DIEGO--(BUSINESS WIRE)--Jun. 6, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018, at 10:40 a.m. Pacific Time in Rancho Palos Verdes, California. ... 
Printer Friendly Version
05/08/18ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018
SAN DIEGO--(BUSINESS WIRE)--May 8, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference 2018 on Tuesday, May 15, 2018, at 10:40 a.m. Pacific Time in Las Vegas. A live webcast of... 
Printer Friendly Version
05/04/18ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results
– Strong Performance for NUPLAZID® in First Quarter 2018 – First Quarter Net Sales Grew to $48.9 Million, Representing a 12% Sequential Increase Over 4Q17 and 220% Increase Over 1Q17 – ACADIA Reiterates 2018 Net Sales Guidance of $255 Million to $270 Million SAN DIEGO--(BUSINESS WIRE)--May 4, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of... 
Printer Friendly Version
05/02/18ACADIA Pharmaceuticals Announces Appointment of Elena Ridloff, CFA, as Senior Vice President, Investor Relations
SAN DIEGO--(BUSINESS WIRE)--May 2, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Elena Ridloff, CFA, has been appointed to the newly created position of Senior Vice President, Investor Relations, leading investor and financial communications activities. She... 
Printer Friendly Version
05/01/18ACADIA Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 4, 2018
ACADIA to Host Conference Call and Webcast on Friday, May 4, 2018, at 8:30 a.m. Eastern Time SAN DIEGO, Calif.--(BUSINESS WIRE)--May 1, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the first quarter e... 
Printer Friendly Version
04/27/18ACADIA Pharmaceuticals Announces Presentation of Clinical Experience Data for NUPLAZID (Pimavanserin) at 2018 American Academy of Neurology (AAN) Annual Meeting
Two Independent Data Sets Confirm NUPLAZID Is Well-Tolerated and Efficacious in Treating Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis SAN DIEGO--(BUSINESS WIRE)--Apr. 27, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced post... 
Printer Friendly Version
04/27/18ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile of NUPLAZID
- Concurrently, the Company Has Issued a Press Release Announcing the Presentation of Clinical Experience Data for NUPLAZID at the American Academy of Neurology (AAN) Annual Meeting SAN DIEGO--(BUSINESS WIRE)--Apr. 27, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today issued the following statement: NUPLAZID® (pimavanserin) is the only medicine approved in the United States to treat hallucinations and delusions associated... 
Printer Friendly Version
04/23/18PMDAlliance and ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact of Non-Movement Symptoms of Parkinson’s Disease
Results underscore need for greater awareness of non-movement symptoms this Parkinson’s Disease Awareness Month TUCSON, Ariz. & SAN DIEGO--(BUSINESS WIRE)--Apr. 23, 2018-- As part of Parkinson’s Disease Awareness Month, the Parkinson & Movement Disorder Alliance (PMDAlliance) and ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the results of a survey on the impact of non-movement symptoms on people with Parkinson’s disease (PD), a ... 
Printer Friendly Version
03/20/18ACADIA Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018
SAN DIEGO--(BUSINESS WIRE)--Mar. 20, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018, at 11:30 a.m. Eastern Time in New York City. A live webcast of ACADIA’... 
Printer Friendly Version
03/06/18ACADIA Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference on March 13, 2018
SAN DIEGO--(BUSINESS WIRE)--Mar. 6, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018, at 8:40 a.m. Eastern Time in Boston. A live webcast of ACADI... 
Printer Friendly Version
02/27/18ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
-Fourth Quarter and Full Year 2017 Net Sales Grew to $43.6 Million and $124.9 Million, Respectively SAN DIEGO--(BUSINESS WIRE)--Feb. 27, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December... 
Printer Friendly Version
02/20/18ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018
ACADIA to Host Conference Call and Webcast on Tuesday, February 27, 2018, at 5:00 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)--Feb. 20, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the fourth quarter... 
Printer Friendly Version
01/02/18ACADIA Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 9, 2018
SAN DIEGO--(BUSINESS WIRE)--Jan. 2, 2018-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018, at 1:30 p.m. Pacific Time in San Francisco. A live webcast of ACAD... 
Printer Friendly Version